CROs Improve Service Delivery
Applied Clinical Trials
ISR Reports' data show the CRO industry is improving service delivery, albeit with room for improvement. Not long ago- perhaps as recent as 2005-this chart would have been reversed, when more service providers were missing expectations than exceeding them.
ISR Reports' data show the CRO industry is improving service delivery, albeit with room for improvement. Not long ago— perhaps as recent as 2005—this chart would have been reversed, when more service providers were missing expectations than exceeding them.
So why the change? We have identified the following three factors:
- The increasingly competitive CRO environment is responsible for some of the quality improvements. Disaffected customers have more options than they used to, providing CROs with all the incentive needed to tighten the bolts on their clinical operations machinery.
- Similarly, CROs are getting better at asking the right questions and identifying their customers' needs.
- And for their part, we would suggest that sponsors are also becoming more sophisticated outsourcers They are getting better at articulating their needs, making it more likely that CROs can meet them.
Sponsors Rate Satisfaction with CROs
With 20% of interactions still missing expectations more can be done. But in our experience, these relationships have come a long way—Industry Standard Reports, www.ISRreports.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
First Patient Dosed in Phase III Trial of Enhertu as First-Line Treatment for Endometrial Cancer
June 10th 2025In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 study for the treatment of patients with HER2-expressing, mismatch repair proficient primary advanced or recurrent endometrial cancer.
